Want to see KR:102460 full AI Analyst Report?
Top Page
Reyon Pharmaceutical Co., Ltd.
(102460)
Select Model
Select Model
Rating:44Neutral
Price Target:
₩9,428.00
Action:N/A
Date:10/28/26
The score is held down primarily by weak financial performance (losses, steep revenue decline, and limited cash-flow coverage of debt) and bearish technical conditions (price below key moving averages with negative MACD). Valuation offers limited support because the negative P/E is driven by losses and no dividend yield data is available.
Positive Factors
Integrated pharmaceutical business model
Reyon spans research, development, manufacturing, and commercialization, giving it an integrated pharmaceutical operating model. This breadth can support control over product development and commercialization and provides multiple avenues for rebuilding revenue over the medium term.
Negative Factors
Sharp profitability deterioration
The shift from earlier modest profitability to large losses represents a material deterioration in earnings power. Deeply negative operating and net margins can consume capital, restrict reinvestment, and make a sustained recovery dependent on substantial operational improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated pharmaceutical business model
Reyon spans research, development, manufacturing, and commercialization, giving it an integrated pharmaceutical operating model. This breadth can support control over product development and commercialization and provides multiple avenues for rebuilding revenue over the medium term.
Read all positive factors
Reyon Pharmaceutical Co., Ltd. (102460) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩177.54B
Dividend Yield1.41%
Average Volume (3M)23.00K
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue Growth-4.45%
EPS Growth-250.71%
CountryKR
Employees457
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1868.60
Shares Outstanding18,586,811
10 Day Avg. Volume28,502
30 Day Avg. Volume23,001
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.91
Price to Sales (P/S)1.37
P/FCF Ratio-29.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Reyon Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Operating both domestically in South Korea and across international markets, REYON Pharmaceutical Co., Ltd. specializes in the production and distribution of pharmaceutical products and active pharmaceutical ingredients (APIs). The company's diver...
Reyon Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
43
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 143.37B | 145.93B | 148.30B | 151.07B | 154.04B | 142.80B |
| Gross Profit | 30.80B | 33.76B | 72.79B | 78.90B | 81.73B | 79.44B |
| EBITDA | -15.42B | 228.10M | 12.76B | 9.01B | 13.52B | 6.21B |
| Net Income | -34.44B | -29.83B | 4.15B | 3.58B | 7.43B | 5.54B |
Balance Sheet | ||||||
| Total Assets | 444.37B | 465.05B | 499.99B | 499.78B | 484.69B | 477.98B |
| Cash, Cash Equivalents and Short-Term Investments | 7.04B | 6.78B | 10.21B | 24.24B | 36.07B | 97.45B |
| Total Debt | 216.85B | 216.12B | 204.05B | 225.05B | 210.20B | 207.31B |
| Total Liabilities | 249.50B | 244.97B | 250.05B | 251.15B | 236.93B | 232.74B |
| Stockholders Equity | 194.87B | 220.08B | 249.94B | 248.62B | 247.77B | 245.24B |
Cash Flow | ||||||
| Free Cash Flow | 906.03M | -6.69B | -17.46B | -20.23B | -54.40B | -105.31B |
| Operating Cash Flow | 5.95B | 1.23B | -1.44B | 8.65B | 8.73B | 11.68B |
| Investing Cash Flow | -4.67B | -7.34B | -16.59B | -8.74B | -52.56B | -114.68B |
| Financing Cash Flow | -3.14B | 2.36B | 4.13B | 8.15B | -6.77B | 157.58B |
Reyon Pharmaceutical Co., Ltd. Technical Analysis
Negative
―
Price Trends
9993.60
Negative
10007.20
Negative
10421.70
Negative
Market Momentum
-83.03
Positive
33.83
Neutral
50.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:102460, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 9954.00, equal to the 50-day MA of 9993.60, and equal to the 200-day MA of 10421.70, indicating a bearish trend. The MACD of -83.03 indicates Positive momentum. The RSI at 33.83 is Neutral, neither overbought nor oversold. The STOCH value of 50.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:102460.
Reyon Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₩225.55B | 10.30 | ― | 4.16% | 0.28% | 16.80% | |
59 Neutral | ₩169.24B | 2.61 | ― | 3.94% | 1.43% | 106.56% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₩212.70B | 59.83 | ― | 0.44% | 11.35% | 204.54% | |
50 Neutral | ₩169.19B | 63.80 | ― | 3.22% | 1.83% | -67.89% | |
44 Neutral | ₩177.54B | -5.13 | ― | 1.41% | -4.45% | -250.71% | |
40 Underperform | ₩173.93B | -28.12 | ― | ― | 0.60% | -6964.46% |
* General Sector Average
KR:102460
Reyon Pharmaceutical Co., Ltd.
9,680.00
-1,320.00
-12.00%
KR:001630
Chong Kun Dang Holdings Co., Ltd.
35,550.00
-9,206.72
-20.57%
KR:003220
Daewon Pharmaceutical Co., Ltd
7,760.00
-5,120.31
-39.75%
KR:003520
YUNGJIN PHARM. CO. LTD
951.00
-1,089.00
-53.38%
KR:004310
Hyundai Pharmaceutical Co., Ltd.
6,880.00
3,159.39
84.92%
KR:005500
Samjin Pharmaceutical Co., Ltd.
19,240.00
174.53
0.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.